Abstract

The development of novel inhaled drug products offers a promising approach to delivering targeted therapy for respiratory conditions with reduced systemic side effects. This article explores the critical pharmacokinetic (PK) and pharmacodynamic (PD) considerations crucial for optimizing these inhaled therapies. Key PK factors include drug deposition, absorption, metabolism, and elimination, all of which influence the drug's efficacy and safety. PD considerations focus on receptor binding, onset and duration of action, and safety profiles. By examining these aspects, we aim to provide insights into enhancing the effectiveness and patient adherence of inhaled drug products, addressing current challenges, and identifying future research directions